Ge Gao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ge Gao has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Qihui Wu
Translational Research Institute of Brain and Brain-Like Intelligence, Shanghai Fourth People’s Hospital Affiliated to Tongji University School of Medicine, Shanghai Research Institute for Intelligent Autonomous Systems, State Key Laboratory of Cardiology and Medical Innovation Center, Shanghai East Hospital, School of Medicine, Tongji University
4 shared publications - Jialin Charles Zheng
Center for Translational Neurodegeneration and Regenerative Therapy, Tongji Hospital Affiliated to Tongji University School of Medicine, Shanghai, China
2 shared publications Ming Zhang
Tongji Hospital affiliated to Tongji University School of Medicine
2 shared publicationsYizhao Ma
2 shared publicationsBiqi Zou
Tongji Hospital affiliated to Tongji University School of Medicine
1 shared publication- Jiale Han
Stomatology Hospital Affiliated to Tongji University, Tongji University, Shanghai, China
1 shared publication
Latest Publications
- Open Access
- 20 May 2026
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 22 (1) , 2664985
Immunotherapeutic landscape of amyotrophic lateral sclerosis: A bibliometric analysis of research trends, translational priorities, and collaboration networks (2006–2025)
Amyotrophic lateral sclerosis (ALS) remains a major therapeutic challenge, with immune dysregulation increasingly recognized as a critical driver of disease progression. Despite extensive mechanistic research, no immunotherapeutic approach has achieved consistent disease-modifying effects, raising questions about whether this translational gap reflects biological complexity or structural misalignment within the research ecosystem. To characterize the intellectual evolution of ALS immunotherapeutics research, identify immune targets with translational potential, and evaluate collaboration patterns that may influence translational efficiency, we performed a bibliometric analysis of 2,256 publications indexed in Web of Science and Scopus using network-based approaches including co-citation clustering, keyword co-occurrence, and citation burst detection implemented in CiteSpace, VOSviewer, and R-Bibliometrix. Publication output increased 8.4-fold over the study period, delineating three developmental phases. Thematic analyses revealed a shift from early emphasis on microglial biology and SOD1-based models toward recent focus areas including the gut-brain axis, C9orf72-associated immune dysregulation, and advanced immunomodulatory strategies. Collaboration networks remain predominantly regional despite strong contributions from the United States, Europe, and Asia, with limited integration between mechanistic research groups and clinical trial consortia. Among immune-directed therapeutic strategies, regulatory T cell modulation and microglial-targeted approaches exhibit the highest translational readiness. These findings suggest that the lack of effective ALS immunotherapeutics reflects not only biological complexity but also structural and strategic misalignment within the research ecosystem. This bibliometric analysis provides a systems-level framework to guide more integrated translational strategies in ALS immunotherapeutics development.
- 20 May 2026
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 22 (1) , 2664985
Open AccessImmunotherapeutic landscape of amyotrophic lateral sclerosis: A bibliometric analysis of research trends, translational priorities, and collaboration networks (2006–2025)
Amyotrophic lateral sclerosis (ALS) remains a major therapeutic challenge, with immune dysregulation increasingly recognized as a critical driver of disease progression. Despite extensive mechanistic research, no immunotherapeutic approach has achieved consistent disease-modifying effects, raising questions about whether this translational gap reflects biological complexity or structural misalignment within the research ecosystem. To characterize the intellectual evolution of ALS immunotherapeutics research, identify immune targets with translational potential, and evaluate collaboration patterns that may influence translational efficiency, we performed a bibliometric analysis of 2,256 publications indexed in Web of Science and Scopus using network-based approaches including co-citation clustering, keyword co-occurrence, and citation burst detection implemented in CiteSpace, VOSviewer, and R-Bibliometrix. Publication output increased 8.4-fold over the study period, delineating three developmental phases. Thematic analyses revealed a shift from early emphasis on microglial biology and SOD1-based models toward recent focus areas including the gut-brain axis, C9orf72-associated immune dysregulation, and advanced immunomodulatory strategies. Collaboration networks remain predominantly regional despite strong contributions from the United States, Europe, and Asia, with limited integration between mechanistic research groups and clinical trial consortia. Among immune-directed therapeutic strategies, regulatory T cell modulation and microglial-targeted approaches exhibit the highest translational readiness. These findings suggest that the lack of effective ALS immunotherapeutics reflects not only biological complexity but also structural and strategic misalignment within the research ecosystem. This bibliometric analysis provides a systems-level framework to guide more integrated translational strategies in ALS immunotherapeutics development.
- Open Access
- 1 April 2026
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 15 (4) , 250
Translational progress and bottlenecks in neurotransmitter-cancer research [2000–2025]: an integrated bibliometric and interventional trial analysis
Background: Neurotransmitter signaling influences cancer initiation, progression, and therapy response. We systematically characterized the field’s intellectual structure, thematic evolution, and translational trajectory. Methods: We analyzed 2,823 Web of Science articles [2000–2025] with CiteSpace and Bibliometrix, and reviewed 76 interventional trials from ClinicalTrials.gov to assess translational activity, drug-class distribution, and trial design trends. Results: Annual output nearly tripled, with >50% of papers published after 2020. The US led productivity (26.2%) and impact; China showed rapid output growth (18.1%). Oncology trials with tumor efficacy endpoints were dominated by β-adrenergic antagonists (33%), histone deacetylase (HDAC) inhibitors (16%), selective serotonin reuptake inhibitors (SSRIs) (22%), and dopamine modulators (13%). Since 2018, immunotherapy combinations increased (8 trials). Trials were skewed toward early-phase, and trial design heterogeneity and limited biomarker integration were common. Translational linkage was limited: only 4.5% of publications connected to identifiable trials. The neurotransmitter-immune axis emerged as a central translational theme. Conclusions: Neurotransmitter-cancer research has expanded rapidly but shows substantial translational attrition. Findings support continued evaluation of β-blockers in late-phase trials, prioritized testing of SSRI-immunotherapy combinations, and exploration of underrepresented GABAergic and cholinergic pathways. We recommend harmonized preclinical-to-clinical pipelines and accelerated biomarker development to improve translation. This evidence-based map can guide targeted translational strategies in neurotransmitter-directed oncology and precision oncology.
- 1 April 2026
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 15 (4) , 250
Open AccessTranslational progress and bottlenecks in neurotransmitter-cancer research [2000–2025]: an integrated bibliometric and interventional trial analysis
Background: Neurotransmitter signaling influences cancer initiation, progression, and therapy response. We systematically characterized the field’s intellectual structure, thematic evolution, and translational trajectory. Methods: We analyzed 2,823 Web of Science articles [2000–2025] with CiteSpace and Bibliometrix, and reviewed 76 interventional trials from ClinicalTrials.gov to assess translational activity, drug-class distribution, and trial design trends. Results: Annual output nearly tripled, with >50% of papers published after 2020. The US led productivity (26.2%) and impact; China showed rapid output growth (18.1%). Oncology trials with tumor efficacy endpoints were dominated by β-adrenergic antagonists (33%), histone deacetylase (HDAC) inhibitors (16%), selective serotonin reuptake inhibitors (SSRIs) (22%), and dopamine modulators (13%). Since 2018, immunotherapy combinations increased (8 trials). Trials were skewed toward early-phase, and trial design heterogeneity and limited biomarker integration were common. Translational linkage was limited: only 4.5% of publications connected to identifiable trials. The neurotransmitter-immune axis emerged as a central translational theme. Conclusions: Neurotransmitter-cancer research has expanded rapidly but shows substantial translational attrition. Findings support continued evaluation of β-blockers in late-phase trials, prioritized testing of SSRI-immunotherapy combinations, and exploration of underrepresented GABAergic and cholinergic pathways. We recommend harmonized preclinical-to-clinical pipelines and accelerated biomarker development to improve translation. This evidence-based map can guide targeted translational strategies in neurotransmitter-directed oncology and precision oncology.
- Open Access
- 29 October 2025
- Published by Wiley in Brain and Behavior
- Vol. 15 (11) , e71023
Aggregation and Propagation of α‐Synuclein in Parkinson's Disease: A Bibliometric Perspective
Introduction: Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the aggregation and propagation of alpha‐synuclein (α‐syn), processes that contribute to neuronal dysfunction and cell death. Although substantial progress has been made in understanding α‐syn pathology, a comprehensive bibliometric evaluation of global trends in this field remains lacking. This study aims to systematically map the research landscape surrounding α‐syn aggregation and propagation in PD, offering insights into its molecular mechanisms and clinical relevance. Methods: A bibliometric analysis was conducted using data retrieved from the Web of Science Core Collection (WoSCC) spanning 2005 to 2024. The data were processed and analyzed with R‐Bibliometrix, VOSviewer, and CiteSpace to quantify publication trends, international collaborations, influential authors and institutions, journal impact, and keyword co‐occurrence networks. Results: A total of 3220 relevant articles were identified. The number of annual publications steadily increased, reflecting growing scholarly interest. The United States, China, and the United Kingdom emerged as leading contributors. Robust international collaborations were observed, especially among Western countries, with the University of California System identified as the most prolific institution. Two primary thematic clusters were revealed: (1) “aggregation,” focusing on the roles of “mitochondria” and “lysosomes,” and (2) “propagation,” highlighting the involvement of “exosomes” and “microglia.” Emerging research frontiers included “biomarkers” and “neuroinflammation,” with a recent trend shifting toward studies on the propagation of α‐syn. Conclusion: This study underscores a paradigm shift in PD research from α‐syn aggregation to propagation, emphasizing the significance of exosomes, microglia, and systemic inflammation in disease pathogenesis. These findings provide a comprehensive roadmap for future research, highlighting the need for interdisciplinary collaboration and the development of targeted therapeutic strategies.
- 29 October 2025
- Published by Wiley in Brain and Behavior
- Vol. 15 (11) , e71023
Open AccessAggregation and Propagation of α‐Synuclein in Parkinson's Disease: A Bibliometric Perspective
Introduction: Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the aggregation and propagation of alpha‐synuclein (α‐syn), processes that contribute to neuronal dysfunction and cell death. Although substantial progress has been made in understanding α‐syn pathology, a comprehensive bibliometric evaluation of global trends in this field remains lacking. This study aims to systematically map the research landscape surrounding α‐syn aggregation and propagation in PD, offering insights into its molecular mechanisms and clinical relevance. Methods: A bibliometric analysis was conducted using data retrieved from the Web of Science Core Collection (WoSCC) spanning 2005 to 2024. The data were processed and analyzed with R‐Bibliometrix, VOSviewer, and CiteSpace to quantify publication trends, international collaborations, influential authors and institutions, journal impact, and keyword co‐occurrence networks. Results: A total of 3220 relevant articles were identified. The number of annual publications steadily increased, reflecting growing scholarly interest. The United States, China, and the United Kingdom emerged as leading contributors. Robust international collaborations were observed, especially among Western countries, with the University of California System identified as the most prolific institution. Two primary thematic clusters were revealed: (1) “aggregation,” focusing on the roles of “mitochondria” and “lysosomes,” and (2) “propagation,” highlighting the involvement of “exosomes” and “microglia.” Emerging research frontiers included “biomarkers” and “neuroinflammation,” with a recent trend shifting toward studies on the propagation of α‐syn. Conclusion: This study underscores a paradigm shift in PD research from α‐syn aggregation to propagation, emphasizing the significance of exosomes, microglia, and systemic inflammation in disease pathogenesis. These findings provide a comprehensive roadmap for future research, highlighting the need for interdisciplinary collaboration and the development of targeted therapeutic strategies.
- Open Access
- 12 August 2024
- Published by Elsevier in International Dental Journal
- Vol. 75 (2) , 564-574
Research Trends in the Comorbidity Between Periodontitis and Neurodegenerative Diseases
- 12 August 2024
- Published by Elsevier in International Dental Journal
- Vol. 75 (2) , 564-574
Open AccessResearch Trends in the Comorbidity Between Periodontitis and Neurodegenerative Diseases